Prurigo Nodularis Epidemiology Forecast

"DelveInsight’s ‘Prurigo nodularis (PN)—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Prurigo nodularis (PN) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. 


Geographies Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan


Study Period: 2017–2030


Prurigo nodularis (PN) Understanding

Prurigo nodularis (PN) is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution. PN is accompanied by long-standing pruritus and is developed as a reaction to repeated scratching in patients with Chronic Prurigo (CP) from various etiologies, including dermatological, systemic, infectious, and psychiatric. Although most patients present with several associated conditions may explain the development of CP, there is a significant percentage (~13%) that do not have an identifiable illness or predisposing condition that would serve as an initial trigger. It can be diagnosed clinically by visual examination, as these are large, more or less symmetrical nodules with intense itching. There are several conditions which resemble PN, such as lichen planus, psoriasis, even eczema at times. The differential diagnoses are delineated in as some of the skin inflammatory conditions most closely linked with the PN.

Chronic pruritus has gained substantial research attention in recent years resulting in a more comprehensive understanding of this condition. However, Prurigo, which occurs along with chronic pruritus and presents with symmetrically distributed intensively itchy papules, nodules and/or plaques, remains relatively unexplored.


Prurigo nodularis (PN) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalence of prurigo nodularis, gender-specific diagnosed prevalence of prurigo nodularis, age-specific diagnosed prevalence of prurigo nodularis, type-specific prevalent population of prurigo nodularis, and severity-specific diagnosed prevalent population of prurigo nodularis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.


Prurigo nodularis (PN) Detailed Epidemiology Segmentation

• Prevalent population of Prurigo nodularis in 7MM is expected to increase at a CAGR of 0.63% for the study period, i.e., 2017–2030.

• Among the 7MM countries in 2017, the largest patient pool was accounted by the United States. On the other hand, Japan comprised the least number of cases affected by PN.

• EU comprised ~38% of the patient pool for PN in 2017.  

• As per DelveInsight analysis, it has been observed that most of the patients with Prurigo nodularis diagnosed with atopic than non-Atopic.

• Estimates reveal that the overall diagnosed prevalence of PN follows an increasing trend with an increase in severity of the symptoms, such that moderate cases account for maximum diagnosed prevalent cases, followed by severe and mild cases.


Scope of the Report

• The report covers the descriptive overview of Prurigo nodularis (PN), explaining its causes, signs and symptoms, pathophysiology and currently available therapies.

• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.

• The report assesses the disease risk and burden and highlights the unmet needs of Prurigo nodularis (PN).

• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Prurigo nodularis (PN), Total Diagnosed and TreatedCases of Prurigo nodularis (PN).


Report Highlights

• Eleven-Year Forecast of Prurigo nodularis (PN)

• 7MM Coverage 

• Diagnosed Prevalence of Prurigo nodularis

• Gender-specific Diagnosed Prevalence of Prurigo nodularis

• Age-specific Diagnosed Prevalence of Prurigo nodularis

• Type-specific Prevalent Population of Prurigo nodularis

• Severity-specific Diagnosed Prevalent Population of Prurigo nodularis


Key Questions Answered

• What is the disease risk, burden and unmet needs of Prurigo nodularis (PN)?

• What is the historical Prurigo nodularis (PN) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?

• What would be the forecasted patient pool of Prurigo nodularis (PN) at the 7MM level?

• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Prurigo nodularis (PN)?

• Out of the above-mentioned countries, which country would have the highest prevalent population of Prurigo nodularis (PN) during the forecast period (2020–2030)?

• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?


Reasons to buy

The Prurigo nodularis (PN) report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Prurigo nodularis (PN) market.

• Quantify patient populations in the 7MM Prurigo nodularis (PN) market to improve product design, pricing, and launch plans.

• The Prurigo nodularis (PN) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.

• The Prurigo nodularis (PN) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.


Key Assessments

• Patient Segmentation

• Disease Risk and Burden

• Risk of disease by the segmentation 

• Factors driving growth in a specific patient population

1 Key Insights

2 Prurigo nodularis (PN): Patient Overview at a Glance

2.1 Total Patient Share (%) Distribution of PN in 2017

2.2 Total Patient Share (%) Distribution of PN in 2030

3 Executive Summary

4 SWOT Analysis

5 Disease Background and Overview of Prurigo nodularis (PN)

5.1 Introduction

5.2 Classification

5.3 Clinical Signs and Symptoms

5.4 Pathophysiology

5.5 Etiology

5.5.1 Skin Disorders

5.5.2 Systemic Disorders

5.5.3 Psychiatric disorders

5.5.4 Associated Conditions

5.6 Diagnosis

5.7 Management

6 Recognized Establishments

7 Epidemiology and Patient Population: Prurigo nodularis (PN)

7.1 Key Findings

7.2 Epidemiology Methodology

7.3 KOL Views

7.4 7MM Total Diagnosed Prevalent Population of Prurigo nodularis

8 Country-wise Epidemiology of Prurigo nodularis

8.1 United States

8.1.1 Assumptions and Rationale

8.1.2 Diagnosed Prevalence of Prurigo nodularis in the United States

8.1.3 Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United States

8.1.4 Age-specific Diagnosed Prevalence of Prurigo nodularis in the United States

8.1.5 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in the United States

8.1.6 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United States

8.2 EU5 Countries

8.2.1 Assumptions and Rationale

8.3 Germany

8.3.1 Diagnosed Prevalence of Prurigo nodularis in Germany

8.3.2 Gender-specific Diagnosed Prevalence of Prurigo nodularis in Germany

8.3.3 Age-specific Diagnosed Prevalence of Prurigo nodularis in Germany

8.3.4 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in Germany

8.3.5 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Germany

8.4 France

8.4.1 Diagnosed Prevalence of Prurigo nodularis in France

8.4.2 Gender-specific Diagnosed Prevalence of Prurigo nodularis in France

8.4.3 Age-specific Diagnosed Prevalence of Prurigo nodularis in France

8.4.4 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in France

8.4.5 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in France

8.5 Italy

8.5.1 Diagnosed Prevalence of Prurigo nodularis in Italy

8.5.2 Gender-specific Diagnosed Prevalence of Prurigo nodularis in Italy

8.5.3 Age-specific Diagnosed Prevalence of Prurigo nodularis in Italy

8.5.4 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in Italy

8.5.5 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Italy

8.6 Spain

8.6.1 Diagnosed Prevalence of Prurigo nodularis in Spain

8.6.2 Gender-specific Diagnosed Prevalence of Prurigo nodularis in Spain

8.6.3 Age-specific Diagnosed Prevalence of Prurigo nodularis in Spain

8.6.4 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in Spain

8.6.5 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Spain

8.7 United Kingdom

8.7.1 Diagnosed Prevalence of Prurigo nodularis in the United Kingdom

8.7.2 Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom

8.7.3 Age-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom

8.7.4 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in the United Kingdom

8.7.5 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United Kingdom

8.8 Japan

8.8.1 Assumption and Rationale

8.8.2 Diagnosed Prevalence of Prurigo nodularis in Japan

8.8.3 Gender-specific Diagnosed Prevalence of Prurigo nodularis in Japan

8.8.4 Age-specific Diagnosed Prevalence of Prurigo nodularis in Japan

8.8.5 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in Japan

8.8.6 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Japan

9 Appendix

10 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

Table 1: Summary of Prurigo nodularis, Epidemiology, and Key Events (2017–2030)

Table 2: Differential diagnosis of PN

Table 3: Total Diagnosed Prevalent Population of Prurigo nodularis in the 7MM (2017–2030)

Table 4: Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Table 5: Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Table 6: Age-specific Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Table 7: Type-specific Prevalent Population of Prurigo nodularis in the United States (2017–2030)

Table 8: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United States (2017–2030)

Table 9: Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Table 10: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Table 11: Age-specific Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Table 12: Type-specific Prevalent Population of Prurigo nodularis in Germany (2017–2030)

Table 13: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Germany (2017–2030)

Table 14: Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Table 15: Gender-specific Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Table 16: Age-specific Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Table 17: Type-specific Prevalent Population of Prurigo nodularis in France (2017–2030)

Table 18: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in France (2017–2030)

Table 19: Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Table 20: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Table 21: Age-specific Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Table 22: Type-specific Prevalent Population of Prurigo nodularis in Italy (2017–2030)

Table 23: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Italy (2017–2030)

Table 24: Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Table 25: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Table 26: Age-specific Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Table 27: Type-specific Prevalent Population of Prurigo nodularis in Spain (2017–2030)

Table 28: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Spain (2017–2030)

Table 29: Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Table 30: Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Table 31: Age-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Table 32: Type-specific Prevalent Population of Prurigo nodularis in the United Kingdom (2017–2030)

Table 33: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United Kingdom (2017–2030)

Table 34: Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Table 35: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Table 36: Age-specific Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Table 37: Type-specific Prevalent Population of Prurigo nodularis Japan (2017–2030)

Table 38: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Japan (2017–2030)


Figure 1: Prurigo nodularis (PN) SWOT Analysis

Figure 2: PN - Butterfly Sign – No lesion on the center of the back

Figure 3: Symptoms of PN

Figure 4: A section showing orthohyperkeratosis, hypergranulosis, and elongation of the rete ridges, vertical arrangement of collagen fibers, and an increased number of capillaries.

Figure 5: Total Diagnosed Prevalent Patient Population of Prurigo nodularis in the 7MM (2017–2030)

Figure 6: Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Figure 7: Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Figure 8: Age-specific Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Figure 9: Type-specific Prevalent Population of Prurigo nodularis in the United States (2017–2030)

Figure 10: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United States (2017–2030)

Figure 11: Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Figure 12: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Figure 13: Age-specific Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Figure 14: Type-specific Prevalent Population of Prurigo nodularis in Germany (2017–2030)

Figure 15: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Germany (2017–2030)

Figure 16: Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Figure 17: Gender-specific Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Figure 18: Age-specific Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Figure 19: Type-specific Prevalent Population of Prurigo nodularis in France (2017–2030)

Figure 20: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in France (2017–2030)

Figure 21: Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Figure 22: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Figure 23: Age-specific Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Figure 24: Type-specific Prevalent Population of Prurigo nodularis in Italy (2017–2030)

Figure 25: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Italy (2017–2030)

Figure 26: Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Figure 27: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Figure 28: Age-specific Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Figure 29: Type-specific Prevalent Population of Prurigo nodularis in Spain (2017–2030)

Figure 30: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Spain (2017–2030)

Figure 31: Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Figure 32: Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Figure 33: Age-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Figure 34: Type-specific Prevalent Population of Prurigo nodularis in the United Kingdom (2017–2030)

Figure 35: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United Kingdom (2017–2030)

Figure 36: Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Figure 37: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Figure 38: Age-specific Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Figure 39: Type-specific Prevalent Population of Prurigo nodularis in Japan (2017–2030)

Figure 40: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Japan (2017–2030)

  • Tags:
  • Prurigo Nodularis Epidemiology
  • Prurigo Nodularis
  • Prurigo Nodularis Pipeline
  • Prurigo Nodularis Companies
  • Prurigo Nodularis prevalent popula...
  • Prurigo Nodularis incident populat...
  • Prurigo Nodularis patients diagnos...
  • Prurigo Nodularis treatment algori...

Forward to Friend

Need A Quote